Enzo Biochem Names Two New Directors to Its Board; Additions Increase the Company's Board to Eight Members.

Business Editors & Health/Medical Writers

FARMINGDALE, N.Y.--(BW HealthWire)--Aug. 1, 2002

Enzo Biochem, Inc. (NYSE: ENZ), a leading biotechnology company specializing in gene identification and gene regulation technologies for diagnostic and therapeutic applications, today announced the addition of two new directors to the Company's Board of Directors.

The new directors are Stanford S. Warshawsky, Co-President of the investment banking firm of Arnhold and S. Bleichroeder Holdings, Inc., a member firm of The New York Stock Exchange, and Melvin F. Lazar, CPA, founding and managing partner of the public accounting firm of Lazar Levine & Felix (LLF). Their addition brings to eight the total number of directors on the Board of Enzo, including five independent directors.

"We are pleased to have Mr. Lazar and Mr. Warshawsky join our Board," said Elazar Rabbani, Ph.D. Chairman of Enzo. "Their unique backgrounds and broad business experiences will be a valuable addition to our Company, and we are appreciative of their joining Enzo in this important role."

Mr. Warshawsky has been Co-President of Arnold and S. Bleichroeder Holdings since 1994, having joined the firm in 1972. He previously was with the law firm of Shearman & Sterling. Mr. Warshawsky is Co-President of Arnhold and S. Bleichroeder Advisers, Inc., a money management advisory group, in addition to being Chairman of the firm's First Eagle Funds, First Eagle SoGen Funds and First Eagle SoGen Variable Funds, Inc. Mr. Warshawsky is a member of the New York Stock Exchange's Nominating Committee, of which he also was a former Chairman, a member of the Big Board's New York Area Firms Advisory Committee, and a member of the Bar Associations of both New York State and Virginia State. Mr. Warshawsky holds a BA from the University of Michigan and a JD from the University of Virginia School of Law.

Mr. Lazar and his firm have served the business and legal communities for over 30 years. He is an expert on the topic of business valuations and merger and acquisition activities. Lazar Levine & Felix is the 17th largest auditor of publicly held companies in the U.S. Mr. Lazar is a board member and serves as the Chairman of the Audit Committee of privately-owned Active Media Services, Inc., the largest corporate barter company in the nation. Mr. Lazar holds a Bachelor of Business Administration degree from The City College of New York.

About Enzo

Enzo Biochem is engaged in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. The Company's proprietary labeling and detection products for gene sequencing and genetic analysis, with approximately 200 patents worldwide, are sold to the life sciences market throughout the world. The Company's therapeutic division is conducting clinical trials for HIV-1-infected patients and for patients infected with hepatitis B and hepatitis C viruses. The Company also holds a patent covering a method and materials for correcting point mutations or small insertions or deletions of genetic material that would allow for editing and correcting certain abnormalities in genes.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.